Products Used in Early Phase IND Studies
FDA issued a guidance document covering GMP requirements for Phase 1 products.
Thu, Jan 18, 2018 10:00 AM (PST)
Online,
Fremont,
California
Questions? Contact Event Organizer
This event ended
Thu, Jan 18 - 11:15 AM
{{calendarLabel}}
{{dow}}
{{calDate.dayOfMonth}}
Sold Out
Ended
{{calDate.available}}
Visit Fundraiser Page
{{ campaign.name }}
Visit fundraiser page to {{ campaign.ctaLabel.toLowerCase() }}
Visit Fundraiser Page
{{ item.name }}
Overview:
How it may be integrated with the recommendations of the guidance documents on CMC requirements.
Areas Covered in the Session:
Discussion of the elements found in the guidance document for Phase 1 material
What to do at really early stages
What about special IND studies?
What about preclinical studies?
Who Will Benefit:
Regulatory Affairs personnel who coordinate activities for the CMC sections of submissions
QA/QC personnel who need to plan work on early stage material
R & D personnel who will contribute data to CMC sections
Project managers for product development studies
Quality systems auditors
Consultants
Speaker Profile:
Steven S. Kuwahara , Ph.D. is the founder and Principal of GXP BioTechnology LLC, a consulting firm that works in the areas covered by the GLP and GMP of drugs, biologics, and nutraceuticals. Steve has over 30 years of experience in supervising quality control laboratories, including an animal testing facility, and in performing GLP and GMP audits of internal and external testing laboratories .
Event Fee: One Dial-in One Attendee Price: US$150.00
Contact Detail:
Compliance4All DBA NetZealous,
Phone: +1-800-447-9407
Email: support@compliance4All.com
Cart is empty
Tickets
Price
Qty